An emerging generation of endocrine therapies in breast cancer: a clinical perspective

Results from clinical trials of next-generation endocrine

Therapeutic Strategies to Target Activating Estrogen Receptor α

Elacestrant demonstrates strong anti-estrogenic activity in PDX

Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors

publications ipc 2006-2010 - Institut Paoli-Calmettes

An emerging generation of endocrine therapies in breast cancer: a

An Expert's Guide to SABCS 2023: A Preview of the Top Abstracts

Diagnostics, Free Full-Text

ZB716, a steroidal selective estrogen receptor degrader (SERD), is

DNA Methylation and Anticancer Drug Resistance in Gynecological Tumors

Effect of lasofoxifene on the progression of primary tumors

Joseph SPARANO, Albert Einstein College of Medicine, NY